The deadline for this award has already passed.

More information about this award

Award Information PDF
Application Deadline: September 1, 2017

Healthy Minds Canada and Pfizer Canada are strongly committed to improving the health and quality of life of Canadians living with mental illness. The Healthy Minds Canada/Pfizer Canada Workplace Depression Awards are designed to help advance clinical research and patient care in psychiatry by supporting Canadian investigators. All submitted proposals will be evaluated by an external independent review committee comprised of Canadian medical research experts.


There are two awards valued at $25,000 each in the following areas of interest:

  • Research assessing the impact of rapid and early optimization of treatment in depression:
    • On depression and level of functional improvement in workplace productivity, presenteeism and absenteeism
    • To minimize depression relapse in the workplace
    • To minimize the incidence of/mitigate the risks for depression in the workplace (e.g. quality improvement research).
  • Research assessing the impact of psychiatric drug substitution on medication effectiveness and functional recovery in depression with respect to:
    • Efficacy, tolerability and adherence to medication following brand-to-generic switches
    • Efficacy, tolerability and adherence to medication following generic-to-generic switches
    • Understand patient, pharmacist and physician awareness of the potential impact of switches (brand-to-generic or generic-to-generic medications)

Award funds are intended to be operating grants and must contribute towards the direct costs of the research program or project for which the funds are granted. Please note that the budget must be inclusive of institutional overhead where applicable; this amount shall not exceed 20% of the grant application budget. Please note that applicants may not receive a salary, a stipend, or an honorarium from the Award (grant).

Applications & Process:

Applications are due by September 1, 2017              .

Applications will be received via email at [email protected]

Submission will be a single (1) PDF sent to the above email address.

  • Request letter
  • Abstract
  • Proposal
    • The research proposal should be no more than 10 pages (including graphs, tables, figures and excluding references, and no more than 2 manuscripts/published articles). Use standard 1 inch margins, with font size of 10 to 12. Include the following:
    • Clear statement of purpose/aims, Primary and Secondary (if any) endpoints
    • Timeline (Duration, Target start date, Target First Subject First Visit and Last Subject Last Visit dates, Target completion date), methodologies and available facilities/resources
    • Other study details: Settings (single, multiple sites), Type (Phase I/II/III/IV), Inclusion/Exclusion criteria, Target subject enrollment, subject details (age, gender, etc.)
    • Summary of relevant past work that is applicable to the project
    • Summary of potential challenges and plans for addressing those obstacles
    • Expected findings and potential impact of these findings, i.e., how your project will impact the health and quality of life of patients
    • Detailed statistical section: Sample size justification and proposed analysis of the data (a statistician should be able to verify calculations and choice of analyses)
  • CV (PI and possible Co-PI or collaborators; CIHR format from common CV)
  • Detailed budget (itemized)
  • Study deliverables
    • Target date to provide results
    • Planned abstract and/or manuscript submission date (and targeted conference and/or journal)

Questions about the application process should be sent to [email protected].

Please note that our scientific review committee will review all applications starting in October 2017 and the winner will be announced at a ceremony at HMC’s Silver Dinner (November 13, 2017)

Eligibility:

  • Eligible areas of research
    • Any trial involving humans must be conducted in line with ICH guidelines and Canadian regulations (Health Canada).
      • Clinical (involving humans)
      • Outcomes/epidemiological research (e.g. structured surveys, pharmacoeconomics, disease management initiatives)
    • Non-eligible areas of research:
      • Basic Science / Fundamental (animal model, in-vivo / in-vitro)
      • Studies involving the administration / aiming to support the efficacy of a competitor drug or the use of a generic (it is best to address these proposals to the competitor/generic drug companies)
      • Proof of harm or otherwise highly invasive studies (unethical)
      • Studies conflicting with global Pfizer-sponsored programs; please contact [email protected] for more information.
      • Mere repeat of existing studies (lack of innovation)
  • Researcher Eligibility Criteria:
    • M.D., Ph.D. or Pharm.D.
    • Canadian citizen or landed immigrant with permanent Canadian residence
    • Not receiving funding from other pharmaceutical industry for the research proposal that is being submitted
    • Not receiving additional funding from the CIHR or other peer-reviewed Canadian Funding agencies overlapping the scope of the research proposal that is being submitted.
    • Read, understand and you accept the eligibility criteria.
    • Prior to the review, a pre-screening for completeness of applications, respect of eligibility criteria. Incomplete applications and budget will not be considered